What question did this study set out to answer?

This study aims to evaluate the in vivo efficacy of CSL305, a therapeutic antibody targeting complement pathways and FcRn, in specific disease models.

June 21, 2026International Journal of Molecular SciencesOpen Access

In Vivo Efficacy of an Inhibitor of Complement and FcRn in Models of Glomerulonephritis and Collagen-Induced Arthritis Using Human C2 Knock-In Mice

View Full Paper

Ask AI

Bookmark

Authors

HCHelen Cao ANAmelia Nash YDYun Dai

Discussion

Member takes

Overview

Randomized trial assesses CSL305's effects on glomerulonephritis and arthritis, indicating potential therapeutic benefits.

Key Points

This study aims to evaluate the in vivo efficacy of CSL305, a therapeutic antibody targeting complement pathways and FcRn, in specific disease models.
Developed huC2 knock-in mice using homologous recombination to express human complement C2.
Administered CSL305 in two models: anti-gbm glomerulonephritis and collagen autoantibody-induced arthritis.
Measured outcomes included urine albumin levels, kidney cellular infiltration, and clinical scores.
In glomerulonephritis, CSL305 reduced urine albumin and kidney infiltration with significant inhibition of complement activity.
In arthritis, CSL305 showed significant dose-dependent reduction in clinical scores in both prophylactic and therapeutic contexts.
No synergistic effects were observed for both mechanisms in the tested animal models.

Cite This Study

Cao et al. (2026) studied this question.

synapsesocial.com/papers/6a377fdd24f042ddf4c5a2a6 https://doi.org/10.3390/ijms27125525

View Full Paper

Ask AI

Bookmark

June 21, 2026International Journal of Molecular SciencesOpen Access

In Vivo Efficacy of an Inhibitor of Complement and FcRn in Models of Glomerulonephritis and Collagen-Induced Arthritis Using Human C2 Knock-In Mice

View Full Paper

Ask AI

Bookmark

Authors

HCHelen Cao ANAmelia Nash YDYun Dai

Discussion

Member takes

Overview

Randomized trial assesses CSL305's effects on glomerulonephritis and arthritis, indicating potential therapeutic benefits.

Key Points

This study aims to evaluate the in vivo efficacy of CSL305, a therapeutic antibody targeting complement pathways and FcRn, in specific disease models.
Developed huC2 knock-in mice using homologous recombination to express human complement C2.
Administered CSL305 in two models: anti-gbm glomerulonephritis and collagen autoantibody-induced arthritis.
Measured outcomes included urine albumin levels, kidney cellular infiltration, and clinical scores.
In glomerulonephritis, CSL305 reduced urine albumin and kidney infiltration with significant inhibition of complement activity.
In arthritis, CSL305 showed significant dose-dependent reduction in clinical scores in both prophylactic and therapeutic contexts.
No synergistic effects were observed for both mechanisms in the tested animal models.

Cite This Study

Cao et al. (2026) studied this question.

synapsesocial.com/papers/6a377fdd24f042ddf4c5a2a6 https://doi.org/10.3390/ijms27125525

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark